AU2013277217B2 - Methods of treating or preventing periodontitis and diseases associated with periodontitis - Google Patents

Methods of treating or preventing periodontitis and diseases associated with periodontitis Download PDF

Info

Publication number
AU2013277217B2
AU2013277217B2 AU2013277217A AU2013277217A AU2013277217B2 AU 2013277217 B2 AU2013277217 B2 AU 2013277217B2 AU 2013277217 A AU2013277217 A AU 2013277217A AU 2013277217 A AU2013277217 A AU 2013277217A AU 2013277217 B2 AU2013277217 B2 AU 2013277217B2
Authority
AU
Australia
Prior art keywords
weeks
control
compound
pct
periodontitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013277217A
Other languages
English (en)
Other versions
AU2013277217A2 (en
AU2013277217A1 (en
Inventor
George HAJISHENGALLIS
John D. Lambris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2013277217A2 publication Critical patent/AU2013277217A2/en
Publication of AU2013277217A1 publication Critical patent/AU2013277217A1/en
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA reassignment THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Amend patent request/document other than specification (104) Assignors: George Hajishengallis, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
Application granted granted Critical
Publication of AU2013277217B2 publication Critical patent/AU2013277217B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
AU2013277217A 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis Active AU2013277217B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662022P 2012-06-20 2012-06-20
US61/662,022 2012-06-20
US13/801,096 US9579360B2 (en) 2012-06-20 2013-03-13 Methods of treating or preventing periodontitis and diseases associated with periodontitis
US13/801,096 2013-03-13
PCT/US2013/046599 WO2013192319A1 (en) 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis

Publications (3)

Publication Number Publication Date
AU2013277217A2 AU2013277217A2 (en) 2015-01-22
AU2013277217A1 AU2013277217A1 (en) 2015-01-22
AU2013277217B2 true AU2013277217B2 (en) 2018-03-08

Family

ID=49769337

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013277217A Active AU2013277217B2 (en) 2012-06-20 2013-06-19 Methods of treating or preventing periodontitis and diseases associated with periodontitis

Country Status (8)

Country Link
US (2) US9579360B2 (enExample)
EP (1) EP2863949B1 (enExample)
JP (1) JP6363595B2 (enExample)
CN (1) CN104640567A (enExample)
AU (1) AU2013277217B2 (enExample)
CA (1) CA2877299C (enExample)
IN (1) IN2015DN00438A (enExample)
WO (1) WO2013192319A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2753636T (pt) * 2011-09-07 2020-01-21 Univ Pennsylvania Análogos de compstatina com propriedades farmacocinéticas melhoradas
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
EA201691727A1 (ru) 2014-02-25 2017-01-30 Ачиллион Фармасьютикалс, Инк. Фосфонатные соединения для лечения опосредованных комплементом нарушений
ES2895029T3 (es) 2014-06-12 2022-02-17 Ra Pharmaceuticals Inc Modulación de actividad del complemento
HUE056613T2 (hu) 2015-01-28 2022-02-28 Ra Pharmaceuticals Inc Komplementaktivitás modulátorai
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
FI3359555T3 (fi) 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN111163767A (zh) 2017-08-02 2020-05-15 艾其林医药公司 治疗阵发性睡眠性血红蛋白尿症的治疗方案
CN111683672A (zh) 2017-12-04 2020-09-18 Ra制药公司 补体活性调节剂
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
PL3645550T3 (pl) 2018-04-06 2022-04-04 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o zwiększonej rozpuszczalności i ulepszonych właściwościach farmakokinetycznych
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
JP2022502500A (ja) 2018-09-25 2022-01-11 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ阻害剤の形態
JP7471300B2 (ja) 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体介在性疾患を治療するための的を絞った投与
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
EP3941462A4 (en) 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES
TW202102481A (zh) 2019-03-29 2021-01-16 美商Ｒａ製藥公司 補體調節劑和相關方法
BR112021017820A2 (pt) 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento
EP3980047B1 (en) 2019-06-04 2024-02-14 RA Pharmaceuticals, Inc. Inflammatory disease treatment with complement inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166862A1 (en) * 2007-02-05 2010-07-01 Potentia Pharmaceuticals, Inc. Local Complement Inhibition for Treatment of Complement-Mediated Disorders
WO2010132954A1 (en) * 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
WO2011091366A2 (en) * 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc. Methods of treating or preventing periodontitis and diseases associated with periodontitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
JP2001294536A (ja) * 2000-04-12 2001-10-23 Sunstar Inc 歯周病予防・治療剤
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
RS53599B1 (sr) * 2005-05-10 2015-02-27 Intermune, Inc. Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
CA2760839C (en) * 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and c-terminal modifications
US8642614B2 (en) * 2009-09-23 2014-02-04 The Regents Of The University Of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof
WO2011115225A1 (ja) * 2010-03-17 2011-09-22 国立大学法人 鹿児島大学 歯周病特異的ペプチド、並びにそれを用いた歯周病の治療および診断
US10039802B2 (en) * 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
PT2753636T (pt) * 2011-09-07 2020-01-21 Univ Pennsylvania Análogos de compstatina com propriedades farmacocinéticas melhoradas
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166862A1 (en) * 2007-02-05 2010-07-01 Potentia Pharmaceuticals, Inc. Local Complement Inhibition for Treatment of Complement-Mediated Disorders
WO2010132954A1 (en) * 2009-05-21 2010-11-25 Oral Health Australia Pty Ltd Method of treating periodontal disease by administering antagonists of par-2
WO2011091366A2 (en) * 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc. Methods of treating or preventing periodontitis and diseases associated with periodontitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAJISHENGALLIS, G., "Complement and periodontitis", BIOCHEMICAL PHARMACOLOGY, (2010), vol. 80, pages 1992 - 2001 *

Also Published As

Publication number Publication date
CA2877299A1 (en) 2013-12-27
US20170202935A1 (en) 2017-07-20
IN2015DN00438A (enExample) 2015-06-19
US10668135B2 (en) 2020-06-02
CN104640567A (zh) 2015-05-20
AU2013277217A2 (en) 2015-01-22
CA2877299C (en) 2022-07-12
JP2015523999A (ja) 2015-08-20
EP2863949B1 (en) 2019-01-23
AU2013277217A1 (en) 2015-01-22
US20130344082A1 (en) 2013-12-26
JP6363595B2 (ja) 2018-07-25
US9579360B2 (en) 2017-02-28
EP2863949A4 (en) 2016-03-02
EP2863949A1 (en) 2015-04-29
WO2013192319A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
AU2013277217B2 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20220025028A1 (en) Methods of Treating or Preventing Periodontitis and Diseases Associated with Periodontitis
Hajishengallis et al. Complement-dependent mechanisms and interventions in periodontal disease
US20050163764A1 (en) Treatment with agonists of toll-like receptors
Hajishengallis et al. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application
WO2009073916A1 (en) Improved treatment and prophylaxis
EP2018179A1 (en) Use of antagonists of cxcl13 or cxcr5 for treating wounds or fibrotic diseases
Johnstone et al. Calprotectin (S100A8/A9) is an innate immune effector in experimental periodontitis
Kittaka et al. Alveolar bone protection by targeting the SH3BP2‐SYK axis in osteoclasts
Ma et al. Circadian rhythm disruption exacerbates the progression of macrophage dysfunction and alveolar bone loss in periodontitis
Zhou et al. Fusobacterium nucleatum exacerbates the progression of pulpitis by regulating the STING‐dependent pathway
US20140302027A1 (en) Methods of treating periodontal inflammation and periodontal bone loss
US20100035829A1 (en) Method of treating intrauterine inflammation
Snipes et al. Inhibition of sphingosine‐1‐phosphate receptor 2 attenuated ligature‐induced periodontitis in mice
Kawai et al. The mouse experimental periodontitis by silk-ligature placement triggers systemic inflammation potentially exacerbating pulmonary inflammation
CA3044334A1 (en) Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
Moiré et al. Effects of dexamethasone on distribution and function of peripheral mononuclear blood cells in pneumonic calves
Kravets et al. FEATURES OF ANESTESIA PROVISION IN MAXILLO-FACIAL SURGERY IN PATIENTS WITH COMPLICATED MEDICAL HISTORY
Chen et al. Non‐Syndromic Hereditary Gingival Fibromatosis Driven by Chymase Deficiency Is Attenuated by Verteporfin‐Loaded Exosomes
Alshabab RANKL From Osteocytes Contributes to Periodontal Bone Loss
Rittling Evaluation of αlphav integrin role in mouse model induced periapical periodontitis
Allahem Evaluation of αLphav Integrin Role in Mouse
Diogenes et al. Endodontic Infections and Pain
Pacios Pujadó Cellular mechanisms that affect periodontal destruction induced by bacteria infection in diabetic and non diabetic rats
JP2015510887A (ja) 化膿性鼻副鼻腔炎の処置のためのチモシンαの使用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 DEC 2014

HB Alteration of name in register

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Free format text: FORMER NAME(S): GEORGE HAJISHENGALLIS; UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

FGA Letters patent sealed or granted (standard patent)